share_log

Guggenheim Initiates Coverage On Medicenna Therapeutics With Buy Rating, Announces Price Target of C$2

Guggenheim Initiates Coverage On Medicenna Therapeutics With Buy Rating, Announces Price Target of C$2

古根海姆以买入评级启动Medicenna治疗公司的报道,宣布目标价为2加元
Benzinga Real-time News ·  2022/11/29 07:56

Guggenheim analyst Charles Zhu initiates coverage on Medicenna Therapeutics (TSX:MDNA) with a Buy rating and announces Price Target of C$2.

古根海姆分析师Charles朱以买入评级启动Medicenna治疗公司(多伦多证券交易所股票代码:MDNA)的报道,并宣布目标价为2加元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发